

Contents

Preface	xi
Series preface	xv
1 Introduction	1
1.1 The purpose of this chapter	1
1.2 An example	1
1.3 Why are cross-over trials performed?	6
1.4 What are the disadvantages of cross-over trials?	8
1.5 Where are cross-over trials useful?	9
1.6 What attitude to cross-over trials will be adopted in this book?	10
1.7 Carry-over	10
1.8 What may be done about carry-over?	12
1.9 Other attitudes to be adopted	15
2 Some basic considerations concerning estimation in clinical trials*	17
2.1 The purpose of this chapter	17
2.2 Assumed background knowledge	17
2.3 Control in clinical trials	22
2.4 Two purposes of estimation	23
2.5 Some features of estimation	24
2.6 Practical consequences for cross-over trials	28
3 The <i>AB/BA</i> design with Normal data	31
3.1 An example	31
3.2 A simple analysis ignoring the effect of period	33
3.3 Student's approach*	37
3.4 Assumptions in the matched-pairs <i>t</i> approach	37
3.5 Adjusting for a period effect: two-sample <i>t</i> approach	41
3.6 Adjusting for a period effect: the Hills–Armitage approach	42
3.7 Examining period effects*	44
3.8 Testing for carry-over and/or treatment by period interaction*	45
3.9 A model for the <i>AB/BA</i> cross-over*	47
3.10 Carry-over or treatment by period interaction?*	49
3.11 Confidence intervals for carry-over*	50

3.12	Are unbiased estimators of the treatment effect available?*	51
3.13	Can we adjust for carry-over?*	52
3.14	The two-stage analysis*	52
3.15	Use of baseline measurements	54
3.16	Computer analysis	60
3.17	Further reading	69
3.18	Recommendations	69
4	Other outcomes and the <i>AB/BA</i> design	71
4.1	Introduction	71
4.2	Transformations	71
4.3	Non-parametric methods	80
4.4	Binary outcomes	103
4.5	Miscellaneous outcomes	109
5	Normal data from designs with three or more treatments	117
5.1	Why do we have designs with three or more treatments?	117
5.2	Sequences for trials with three or more treatments	120
5.3	Analyses ignoring the effect of period	123
5.4	Allowing for period effects	130
5.5	Other miscellaneous issues	138
5.6	Recommendations	142
6	Other outcomes from designs with three or more treatments	143
6.1	Introduction	143
6.2	Analyses which take no account of period effects	143
6.3	Non-parametric analyses adjusting for period effects	144
6.4	Hodges–Lehmann type estimators*	152
6.5	A stratified period adjusted sign test	153
6.6	Other analyses	155
7	Some special designs	157
7.1	The scope of this chapter	157
7.2	Factorial designs	157
7.3	Incomplete block designs	163
7.4	<i>N</i> of 1 trials	172
7.5	Bioequivalence studies	177
8	Graphical and tabular presentation of cross-over trials	183
8.1	Basic principles	183
8.2	Patient listings	184
8.3	Response by patient scatter-plots	186
8.4	Treatment by treatment scatter-plots	187
8.5	Treatment by treatment histograms	188

8.6	Basic estimator scatter-plots	192
8.7	Effect plots	194
8.8	Treatment centred residual plots	195
9	Various design issues	199
9.1	Introduction	199
9.2	Parallel group or cross-over?	200
9.3	Carry-over and the length of the wash-out period	208
9.4	Choosing sequences for a cross-over	209
9.5	Sample-size issues	211
9.6	Drop-outs, protocol violations and missing observations	219
10	Mathematical approaches to carry-over*	223
10.1	The purpose of this chapter	223
10.2	An illustrative example	224
10.3	Five reasons for believing that the simple carry-over model is not useful	226
10.4	In summary: the case against mathematical approaches to carry-over	237
10.5	Using the simple carry-over model	238
10.6	Where to find out more about the simple carry-over model	249
	References	251
	Author index	259
	Subject index	261